Health Law & Policy

CHLPI Report on Community Joint Use Quoted in The Atlantic

An April 29, 2016 article from The Atlantic looks at the success of Joint Use programs in both San Francisco and New York and the programs’ positive effects on children and the community. Community use, also known as shared use or joint use, refers to the idea of opening public buildings and grounds at times they […]

5/5 | Beating HCV: An Open Forum on Opportunities & Challenges for Treating HCV in MA

The Center for Health Law & Policy Innovation (CHLPI) of Harvard Law School and the Massachusetts Viral Hepatitis Coalition will host Beating HCV: An Open Forum on Opportunities and Challenges for Treating Hepatitis C in Massachusetts on May 5, 2016, from 1:00 – 4:00 pm at the Boston Common Hotel & Conference Center, 40 Trinity Place, Boston, MA 02116. HCV is currently taking […]

CHLPI’s QHP Assessment Noted in Boston Globe Story on Hepatitis C

The latest in a series of articles and op-eds from the Boston Globe, “Hepatitis C patients often have to get sicker before insurance will pay for drugs,”  delves further into the Massachusetts health insurance marketplace and the various insurance providers who have placed restrictions on access to the Hepatitis C cure, despite recommendations from national health […]

CHLPI Litigation Director Quoted in Article from FiercePharma

“New York AG sues insurer over restrictive hep C coverage” originally printed by Emily Wasserman on April 15, 2016 The New York State Attorney General has already taken some steps to find out why insurers are limiting coverage of pricey hep C meds to the sickest patients but has stopped short of suing companies for […]

CHLPI Faculty Director Quoted in Editorial Written by the Boston Globe Editorial Board

An editorial released by the Boston’s Globe’s editorial board on Thursday, April 14th, 2016, calls for insurance providers to allow unfettered access to the Hepatitis C cure for all living with the disease. “Don’t deny hepatitis C patients a cure” follows an article published in the previous Sunday’s Boston Globe, “Hepatitis C drug costs leave […]

CHLPI Director Quoted in Boston Globe Article on Hepatitis C

An April 9th, 2016 article in the Boston Globe quotes CHLPI’s faculty director, Robert Greenwald, as it explores restrictions placed on access to curative medications for Hepatitis C (HCV) for patients enrolled in Medicaid. The article, “Hepatitis C drug costs leave many without care,” profiles various patients who were able to receive the the HCV […]

CHLPI’s Research on Health Insurance Plans Cited in PhRMA

PhRMA, the Pharmaceutical Research and Manufacturers of America, recently posted a story on its blog Catalyst about CHLPI’s 2016 qualified plan assessments and findings. The blog post, titled “New research: Insurance plan structure can have discriminatory effect,” describes the forms of discrimination uncovered by CHLPI’s research, including high cost-sharing. Excerpt from the blog post: “New research from the Harvard […]

CHLPI Faculty Director to be Honored by Harvard Law School Student Government

Robert Greenwald, CHLPI’s Faculty Director and Professor of Law, will be honored by Harvard Law School’s Student Government in April 2016 with the newly created Teaching & Advising Award. The Award is meant to recognize both exemplary instruction and the ability of an instructor to inspire personal and intellectual development outside the classroom. The criteria for […]

My Experience at AIDSWatch

Written by Anthony Parel, Northeastern University Class of 2016, and Winter 2016 Health Law and Policy Intern. Images courtesy of AIDSUnited. Last month, I stepped into a room where idealism could transform into realism through the voices of the strong and battle-tested. It was in this room where individuals from all across the United States […]

CHLPI Clinical Instructor Quoted in Minnesota’s Star Tribune

A March 30, 2016, article from Minnesota’s Star Tribune features an interview with CHLPI’s Carmel Shachar on high costs for AIDS medications. “Advocates decry insurer charges for AIDS drugs in Minnesota” examines the worrisome trend of health insurance providers categorizing certain medications, such as those for HIV/AIDS and Hepatitis C, on the highest,  and most expensive for […]